연구성과로 돌아가기
2024 연구자 정보 (52 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Song, Jae-Yun (Song, JY) |
Korea Univ, Coll Med, Dept Obstet & Gynecol, Anam Hosp, Seoul, South Korea |
|
|
[JCR상위 1.7] Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS) [JCR상위 9.6] Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial) |
SCIE | 1.7 |
ONCOLOGY OBSTETRICS & GYNECOLOGY;ONCOLOGY |
rohjuwon@hanmail.net; | ||
|
Song, Seungho (Song, S) |
|
|
[JCR상위 1.7] Analysis of prognostic factors in uterine cervical malignancy treated with concurrent chemoradiation therapy: A retrospective study in two centers in Korea. | SCIE | 1.7 | ONCOLOGY | ||||
|
Sul, Ji Young (Sul, JY) |
Chungnam Natl Univ Hosp, Dept Surg, Daejeon, South Korea |
|
|
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Suttichaimongkol, Tanita (Suttichaimongkol, T) |
Khon Kaen Univ, Fac Med, Dept Med, Div Gastroenterol & Hepatol, Khon Kaen, Thailand Khon Kaen Univ, Dept Med, Div Gastroenterol & Hepatol, Fac Med, Khon Kaen, Thailand |
JDW-6886-2023 Suttichaimongkol, Tanita |
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Tan, Lu (Tan, L) |
|
|
[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. | SCIE | 1.7 | ONCOLOGY | ||||
|
Teoh, Sui Lynn (Teoh, SL) |
ICON Clin Res, Med Serv, Singapore, Singapore |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Tria, A. (Tria, A) |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | |||
|
Tseng, Kuo-Chih (Tseng, KC) |
Dalin Tzu Chi Gen Hosp, Hualien, Taiwan Dalin Tzu Chi Hosp, Chiayi, Taiwan |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB [JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis |
SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY |
tom.evans@barinthusbio.com; limys@amc.seoul.kr; |
||
|
Tung, Hung-Da (Tung, HD) |
Chi Mei Hosp, Tainan, Taiwan |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Udoye, Stephanie (Udoye, S) |
AstraZeneca, Global Med Dev, Gaithersburg, MD USA |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | SCIE | 1.7 | ONCOLOGY | |||
|
Um, Taegyu (Um, T) |
|
|
[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) |
SCIE | 1.7 | ONCOLOGY | ||||
|
Vardeu, Antonella (Vardeu, A) |
Vaccitech, Harwell, Oxon, South Korea |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Velcheti, Vamsidhar (Velcheti, V) |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Velichko, Yury (Velichko, Y) |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Verma, Ankit (Verma, A) |
제1저자 | 교신저자 |
Indian Inst Toxicol Res, CSIR, Photobiol Lab, Syst Toxicol & Hlth Risk Assessment Grp, Vishvigyan Bhawan 31,Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India Hebrew Univ Jerusalem, Goldyne Savad Inst Gene Therapy, Stem Cell Res Ctr, Hadassah Med Ctr, Ein Kerem Campus, IL-91120 Jerusalem, Israel |
MIK-6721-2025 Verma, Ankit |
|
[JCR상위 1.7] Skin protection from solar ultraviolet radiation using natural compounds: a review | SCIE | 1.7 | CHEMISTRY, MULTIDISCIPLINARY;ENVIRONMENTAL SCIENCES;ENGINEERING, ENVIRONMENTAL | ankit.verma@mail.huji.ac.il;alessandra.zanoletti@unibs.it;2021321530@knu.ac.kr;adelodun.b@unilorin.edu.ng;kumarpankajgkv@gmail.com;foajibade@futa.edu.ng;lsilva8@cuc.edu.co;ankurphillips245@gmail.com;tkarthees@gmail.com;elza.bontempi@unibs.it;ashish.dwivedi1@iitr.res.in; |
페이지 이동: